TETRAULT LYNN A. sold $60K of NEO
TETRAULT LYNN A. sold 5,307 shares of NEOGENOMICS INC (NEO) at $11.29 on 2026-06-09 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the director’s open-market sale amount, price, and confirmation that it was executed under a pre-arranged Rule 10b5-1 plan.
Market read
Provides incremental sentiment data (insider selling) but is typically low-signal due to 10b5-1 pre-arrangement.
What to watch
Look for follow-on insider activity (buys/sells by other insiders) and whether the company has concurrent fundamental news; this filing alone is not decisive.
Background
The article is an SEC Form 4 insider transaction disclosure for Neogenomics (NEO).
Ticker impact
Director Lynn A. Tetrault sold 5,307 shares of Neogenomics on a Rule 10b5-1 plan for ~$59.9K at $11.29/share (SEC Form 4).
Likely limited near-term impact; any effect should be small and fade unless accompanied by other negative catalysts.
The filing is a Form 4 insider transaction with a pre-arranged 10b5-1 plan, which typically reduces interpretive signal versus discretionary selling.
Market effects
No clear sector read-through from a single director’s small 10b5-1 sale.
None.
None.
Counterpoint
10b5-1 sales are often planned for liquidity/tax and may not reflect bearish expectations; the market may ignore it.
Key entities
- issuerNEOGENOMICS INC
Subject of the Form 4 insider transaction disclosure.
- insiderTETRAULT LYNN A.
Director who sold 5,307 shares under a Rule 10b5-1 plan.
